Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Our round-up of notable biotech financings in the last week includes a $120 million direct offering for immunology and inflammation biotech iTeos, and private rounds for Lycia, Attovia, Ajax, and ...

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Detailed price information for Kalaris Therapeutics Inc (KLRS-Q) from The Globe and Mail including charting and trades.

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

The medical devices sector presents opportunities in mega-deals, with a 39% increase in Q3 2025 over Q3 2024. This emphasizes the importance of investing in prevailing themes identified through recent ...